| 1 |
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne Louise Topalian et al. · New England Journal of Medicine
Open access |
14 Jun 2012 |
12,842 |
| 2 |
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Herbert I. Hurwitz, Louis Fehrenbacher, William F. Novotny et al. · New England Journal of Medicine
Open access |
2 Jun 2004 |
11,036 |
| 3 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei et al. · New England Journal of Medicine
Open access |
27 Sep 2015 |
9,557 |
| 4 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 5 |
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al. · New England Journal of Medicine
Open access |
16 Oct 2013 |
6,826 |
| 6 |
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva Swarup Neelapu et al. · New England Journal of Medicine
Open access |
10 Dec 2017 |
6,098 |
| 7 |
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine
Open access |
15 Aug 2012 |
4,645 |
| 8 |
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann Sebastian De Bono et al. · New England Journal of Medicine
Open access |
25 May 2011 |
4,448 |
| 9 |
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al. · The Lancet
Open access |
5 Mar 2016 |
3,762 |
| 10 |
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André et al. · New England Journal of Medicine
Open access |
2 Dec 2020 |
3,130 |
| 11 |
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,868 |
| 12 |
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al. · New England Journal of Medicine
Open access |
30 Sep 2012 |
2,838 |
| 13 |
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al. · New England Journal of Medicine
Open access |
24 Feb 2021 |
2,554 |
| 14 |
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas B. Powles, Joseph P. Eder, Gregg Daniel Fine et al. · Nature
|
25 Nov 2014 |
2,443 |
| 15 |
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude R. Canon et al. · Nature
|
30 Oct 2019 |
2,329 |
| 16 |
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Frederick Lundry Locke et al. · The Lancet Oncology
Open access |
2 Dec 2018 |
2,307 |
| 17 |
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al. · New England Journal of Medicine
Open access |
19 Jun 2013 |
2,283 |
| 18 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 19 |
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul et al. · New England Journal of Medicine
Open access |
5 Dec 2020 |
1,969 |
| 20 |
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al. · New England Journal of Medicine
Open access |
Apr 2020 |
1,874 |
| 21 |
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur S Raje et al. · New England Journal of Medicine
Open access |
May 2019 |
1,775 |
| 22 |
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja et al. · The Lancet
|
24 Jun 2021 |
1,751 |
| 23 |
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst et al. · New England Journal of Medicine
Open access |
30 Sep 2020 |
1,734 |
| 24 |
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology
|
20 May 2019 |
1,711 |
| 25 |
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al. · New England Journal of Medicine
Open access |
22 Jan 2014 |
1,706 |
| 26 |
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al. · Cancer Discovery
Open access |
17 May 2018 |
1,671 |
| 27 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 28 |
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al. · Blood
Open access |
6 Jun 2017 |
1,507 |
| 29 |
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael Robert Migden, Anthony E. Oro et al. · New England Journal of Medicine
Open access |
7 Jun 2012 |
1,464 |
| 30 |
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
Courtney Denton Dinardo et al. · New England Journal of Medicine
Open access |
2 Jun 2018 |
1,458 |
| 31 |
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Michael Robert Migden et al. · New England Journal of Medicine
Open access |
4 Jun 2018 |
1,430 |
| 32 |
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Marion Jennifer Procter, Evandro de Azambuja et al. · New England Journal of Medicine
Open access |
5 Jun 2017 |
1,425 |
| 33 |
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David R. Spigel et al. · Journal of Clinical Oncology
Open access |
2 Feb 2022 |
1,400 |
| 34 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi Krishna Murthy et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
1,345 |
| 35 |
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al. · Nature Medicine
Open access |
29 May 2018 |
1,280 |
| 36 |
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Joseph Antonia et al. · The Lancet Oncology
Open access |
5 Jun 2016 |
1,263 |
| 37 |
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · The Lancet Oncology
Open access |
7 Sep 2016 |
1,235 |
| 38 |
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Do‐Youn Oh et al. · NEJM Evidence
|
Jun 2022 |
1,205 |
| 39 |
Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Paige Hamilton · Nature Reviews Drug Discovery
ReviewOpen access |
7 Nov 2022 |
1,156 |
| 40 |
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Ranjana H. Advani et al. · New England Journal of Medicine
Open access |
31 Oct 2018 |
1,149 |
| 41 |
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw, Todd Michael Bauer, Filippo de Marinis et al. · New England Journal of Medicine
Open access |
18 Nov 2020 |
1,111 |
| 42 |
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne Ellen Pavel, John Daniel Hainsworth, Éric Baudin et al. · The Lancet
|
Dec 2011 |
1,058 |
| 43 |
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Pasi Antero Janne et al. · New England Journal of Medicine
Open access |
3 Jun 2022 |
1,051 |
| 44 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R.D. Johnston et al. · Journal of Clinical Oncology
Open access |
20 Sep 2020 |
1,037 |
| 45 |
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong et al. · British Journal of Cancer
Open access |
Apr 2020 |
974 |
| 46 |
Adjuvant Docetaxel for Node-Positive Breast Cancer
Miguel Martín et al. · New England Journal of Medicine
Open access |
Jun 2005 |
957 |
| 47 |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald Steven Falchook, Georgina Venetia Long, Razelle Kurzrock et al. · The Lancet
Open access |
May 2012 |
946 |
| 48 |
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial, Susanna Joan Jacobus, RAFAEL RICARDO AURELIANO DA FONSECA et al. · Journal of Clinical Oncology
Open access |
25 Oct 2019 |
909 |
| 49 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi et al. · Annals of Oncology
Open access |
25 Apr 2018 |
893 |
| 50 |
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer
Jorge Luis Galeano Niño, Hanrui Wu, Kaitlyn D. LaCourse et al. · Nature
Open access |
16 Nov 2022 |
875 |